Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
ORAQIX is a topical gel combination of lidocaine and prilocaine indicated for periodontal procedures. It delivers local anesthesia directly to the gingival tissue via a periodontal applicator, eliminating the need for needle injections in certain dental settings.
As LOE approaches, brand focus will shift from growth initiatives to lifecycle management and generic defense, with smaller team size expected.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORAQIX offers stable, specialized dental/periodontal expertise but limited growth trajectory as the product approaches loss of exclusivity. Career progression will depend on managing competitive erosion and optimizing market share in a declining revenue environment.
Worked on ORAQIX at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.